Extracellular vesicles from alternatively activated macrophages remodel the injured hepatic niche and promote repair
In the authors' words
Alternatively activated macrophages (AAMs) are in clinical development for acute liver injury, but their mechanisms of action remain incompletely understood. AAM therapy remodels the injured hepatic niche, promoting reparative macrophage states, suppressing inflammatory myeloid programmes and restoring hepatocyte metabolic and biosynthetic programmes. We identify extracellular vesicles released by AAMs (AAM-EVs) as essential mediators of AAM therapeutic activity. AAM-EVs enhance macrophage phagocytosis and induce reparative transcriptional and proteomic responses, including increased TREM2 abundance. Following administration in established APAP injury, AAM-EVs reduce necrosis and neutrophilic inflammation, and promote hepatocellular regeneration, and we observe preferential and rapid association of AAM-EVs with hepatic macrophages alongside reparative phenotypic shift. Moreover, pharmacological inhibition of EV release attenuates parent AAM efficacy and TREM2 macrophage accumulation, while EVs derived from Dicer-deficient AAMs exhibit reduced therapeutic activity, implicating miRNA-associated mechanisms. Comparative single-nucleus transcriptomics reveals overlapping but distinct macrophage and hepatocyte responses to AAMs and AAM-EVs. Together, these findings identify EV-mediated communication as an important mechanism of macrophage-induced liver repair and support the development of AAM-EVs as a cell-free therapeutic strategy.
Appeared: Thursday, November 19. bioRxiv. Preprint, not yet peer-reviewed.